Stay updated on Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial

Sign up to get notified when there's something new on the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.3%
    Check dated 2025-05-01T01:56:54.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T14:21:22.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-09T09:05:15.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T21:19:02.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    6%
    Check dated 2025-02-10T10:36:20.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T09:46:13.000Z thumbnail image

Stay in the know with updates to Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fulvestrant + Neratinib in Breast Cancer (HER2-Signal) Clinical Trial page.